Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
OMER 
Omeros Corporation (OMER)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: OMER (3-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit 138.69% | Avg. Invested days 31 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 490.83M USD | Price to earnings Ratio - | 1Y Target Price 36 |
Price to earnings Ratio - | 1Y Target Price 36 | ||
Volume (30-day avg) 580907 | Beta 2.04 | 52 Weeks Range 2.96 - 13.60 | Updated Date 03/31/2025 |
52 Weeks Range 2.96 - 13.60 | Updated Date 03/31/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.14 |
Earnings Date
Report Date 2025-03-31 | When Before Market | Estimate -0.71 | Actual -0.55 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -26.87% | Return on Equity (TTM) -576.33% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 577148467 | Price to Sales(TTM) 4.93 |
Enterprise Value 577148467 | Price to Sales(TTM) 4.93 | ||
Enterprise Value to Revenue 8.26 | Enterprise Value to EBITDA -1.49 | Shares Outstanding 57949800 | Shares Floating 55373893 |
Shares Outstanding 57949800 | Shares Floating 55373893 | ||
Percent Insiders 4.45 | Percent Institutions 46.16 |
Analyst Ratings
Rating 3.67 | Target Price 36 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold 2 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Omeros Corporation
Company Overview
History and Background
Omeros Corporation was founded in 1994. It is a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for both clinical and commercial use.
Core Business Areas
- Proprietary Complement Platform: Focuses on developing therapies that target the complement system, a part of the immune system.
- GPCR Platform: Develops therapies that target G protein-coupled receptors (GPCRs), a large family of cell surface receptors.
Leadership and Structure
Gregory A. Demopulos, M.D. is the Chairman and CEO. The company has a typical organizational structure for a biopharmaceutical company, with departments for research and development, clinical operations, manufacturing, and commercialization.
Top Products and Market Share
Key Offerings
- Omeros Corporation OMS721/narsoplimab: Used to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). Competitors include Alexion Pharmaceuticals (Soliris and Ultomiris) and other therapies for TMA.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, long development timelines, and stringent regulatory requirements. The complement system and GPCR targets are areas of intense research and development.
Positioning
Omeros is a relatively small biopharmaceutical company focusing on niche markets. Its competitive advantage lies in its proprietary complement and GPCR platforms and the potential of its pipeline products.
Total Addressable Market (TAM)
The TAM for complement-targeted therapies and GPCR-targeted therapies is substantial. Omeros is positioned to capture a portion of this market with its lead product and pipeline.
Upturn SWOT Analysis
Strengths
- Proprietary technology platforms
- Experienced management team
- Narsoplimab Approved
- Strong IP portfolio
Weaknesses
- Reliance on a few key products
- Limited financial resources
- Regulatory uncertainty
- High dependence on Narsoplimab sales
Opportunities
- Expansion into new therapeutic areas
- Partnerships and collaborations
- Acquisition opportunities
- Positive clinical trial results
Threats
- Competition from larger pharmaceutical companies
- Patent challenges
- Regulatory hurdles
- Clinical trial failures
Competitors and Market Share
Key Competitors
- ALXN
- AMGN
- JNJ
Competitive Landscape
Omeros faces competition from larger pharmaceutical companies with more resources. Its advantage lies in its specialized technology and niche market focus.
Major Acquisitions
Rayner Surgical Group
- Year: 2021
- Acquisition Price (USD millions): 189
- Strategic Rationale: Acquisition of global commercial rights to Rayner's ophthalmology franchise.
Growth Trajectory and Initiatives
Historical Growth: Omeros' historical growth has been dependent on the progress of its clinical trials and regulatory approvals.
Future Projections: Future growth projections depend on successful clinical trials, regulatory approvals, and market uptake of its products. Analyst estimates can be found on financial data platforms.
Recent Initiatives: Recent initiatives include expanding clinical trials for its lead product and seeking partnerships for its pipeline products.
Summary
Omeros is a biopharmaceutical company with promising technology platforms. Success hinges on the commercialization of its drugs and the progress of its clinical trials. The company faces challenges from larger competitors and regulatory hurdles. Omeros' financial health is tied to Narsoplimab. Omeros needs to navigate its future with care and strategic partnerships to succeed in the biotech industry.
Similar Companies
- ALXN
- AMGN
- JNJ
- REGN
Sources and Disclaimers
Data Sources:
- Omeros Corporation website
- SEC filings
- Financial news sources (e.g., Yahoo Finance, Bloomberg)
- Analyst reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The data provided is based on publicly available information and may not be complete or accurate. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Omeros Corporation
Exchange NASDAQ | Headquaters Seattle, WA, United States | ||
IPO Launch date 2009-10-08 | Co-Founder, Chairman, CEO & President Dr. Gregory A. Demopulos M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 198 | Website https://www.omeros.com |
Full time employees 198 | Website https://www.omeros.com | ||
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.